All In MedTech

FDA Clearance Tracker · P040024-S142

Restylane® Lyft with Lidocaine

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 4, 2025

Approved

Time to decision

278 days

Received Jan 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P040024-S142
Device name
Restylane® Lyft with Lidocaine
Applicant
Q-Med AB
Applicant location
Uppsala
Received
Jan 30, 2025
Decided
Nov 4, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040024

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for Restylane® Lyft with Lidocaine for subcutaneous and/or supraperiosteal implantation for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild to moderate chin retrusion.

Source documents

Other decisions for Q-Med AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.